Posted by Michael Wonder on 28 Nov 2024
ICER to assess treatment for secondary progressive multiple sclerosis
19 November 2024 - Report will be subject of CTAF meeting in June 2025; draft scoping document open to public comment until 10 December 2024.
The ICER announced today that it will assess the comparative clinical effectiveness and value of tolebrutinib (Sanofi) for the treatment of secondary progressive multiple sclerosis.
